Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model

• Main Authors: Fei-lin Ge (Author), Lan-lan Si (Author), Yan Yang (Author), Yuan-hua Li (Author), Zhong-lin Lv (Author), Wen-hui Liu (Author), Hao Liao (Author), Jun Wang (Author), Jun Zou (Author), Le Li (Author), Hui Li (Author), Zi-lin Zhang (Author), Jia-bo Wang (Author), Xue-chun Lu (Author), Dong-ping Xu (Author), Zhao-fang Bai (Author), Yan Liu (Author), Xiao-he Xiao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mecha...